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Background
Cancers produce soluble and cell-associated molecules
that can suppress or alter antitumor immunity. Preclinical
studies suggest the disease burden may alter the cytokine
profile of helper T cell responses to cancer antigens. We
studied cytokine production by helper T cells responding
to vaccination with 6 melanoma helper peptides (6MHP)
in blood and lymph nodes. We describe here the cytokine
responses as change from baseline.
Experimental design
Thirty-nine patients with stage IIIB-IV melanoma received
a 6MHP vaccine. Antigen-reactive T cells from blood and
draining lymph nodes were exposed to antigen, and super-
natants (days 2 and 5) were assayed by cytokine bead
arrays for Th1 and Th2 cytokines.
Results
The greatest absolute cytokine responses detected were
the levels of IFN-g and IL-5, though high levels of IL-2
were also produced early by lymph node-derived lym-
phocytes. Lymphocytes from patients with clinically
measurable disease produced similar levels of total cyto-
kine as patients with no evidence of disease (NED). For
both disease statuses, the cytokine profile was Th1-
dominant in most patients. Total cytokine production
and individual cytokine levels varied significantly among
patients and varied over time but persisted up to nine
months post-vaccine.
Conclusions
The MHC class II-associated peptides used in this study
induced helper T cells with a Th1-biased cytokine
response in both PBMC and sentinel immunized nodes in
most patients. Patients with or without measurable disease
can mount a Th1 dominant response to these peptides,
which may persist long after the vaccination sequence.
Future studies are needed to test newer vaccine adjuvants
in combination with these peptides.
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